CSL Limited (ASX:CSL)
Australia · Delayed Price · Currency is AUD | Market Cap | 92.93B -11.2% |
| Revenue (ttm) | 22.83B +1.5% |
| Net Income | -3.73B |
| EPS | -7.73 |
| Shares Out | 478.91M |
| PE Ratio | n/a |
| Forward PE | 21.61 |
| Dividend | 4.15 (2.14%) |
| Ex-Dividend Date | Sep 9, 2026 |
| Volume | 941,254 |
| Open | 193.90 |
| Previous Close | 192.20 |
| Day's Range | 192.74 - 194.90 |
| 52-Week Range | 90.00 - 221.76 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | 186.49 (-3.9%) |
| Earnings Date | Feb 10, 2027 |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services ... [Read more]
Analyst Summary
According to 17 analysts, the average rating for CSL stock is "Buy." The 12-month stock price target is $186.49, which is a decrease of -3.90% from the latest price.
News
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ -...
Australia's CSL taps Amazon's cloud unit to boost research pipeline
Australian biotechnology firm CSL said on Tuesday it is collaborating with Amazon's cloud arm to harness AI and cloud technology across its research and clinical development pipeline.
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept.
Trump Administration Reaches Drug Pricing Deals With 9 Companies
The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
CSL Limited Earnings Call Transcript: H2 2026
FY 2026 saw revenue and profit declines, driven by Vifor headwinds and significant impairments, but strong cash flow enabled continued dividends and share buybacks. FY 2027 guidance is for flat revenue and ~5% NPAT growth, with Behring and Seqirus offsetting Vifor's decline.
CSL Limited Slides: H2 2026
CSL Limited has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 17, 2026.
CSL Limited Earnings release: H2 2026
CSL Limited released its H2 2026 earnings on August 17, 2026, summarizing the period's financial results.
CSL Limited Annual report: H2 2026
CSL Limited has published its H2 2026 annual report on August 17, 2026.
Australia's CSL reports 2% fall in annual profit
Australia's CSL on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
CSL to start clinical trials for new immunoglobulin manufacturing process
Australian biotechnology firm CSL said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the same...
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress...
Trump Plans 100% Tariff on Generic Drugs From 2028
President Donald Trump said generic drug manufacturers will have two years to move production to the US or face a 100% import duty. Bloomberg's Mica Soellner reports on what could come next.
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswi...
Australia says CSL unit Seqirus to discontinue Benpen injections from November
Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progr...
CSL Limited Transcript: Investor update
A comprehensive review confirmed the need for transformation, with efficiency measures and commercial enhancements underway. FY 2026 guidance was revised lower due to inventory and pricing headwinds, with significant impairments flagged. Leadership remains confident in a return to profitable growth.
CSL Limited Slides: Investor update
CSL Limited has posted slides in relation to its latest quarterly earnings report, which was published on May 10, 2026.
CSL Limited Press release: Investor update
CSL Limited issued a press release on May 10, 2026, disclosing material business information to investors.
CSL announces expansion of Illinois plasma therapy manufacturing facility
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies a...
CSL Limited Earnings Call Transcript: H1 2026
First half revenue and profit declined due to policy changes, one-off costs, and impairments, but strong cash flow and cost savings supported an expanded share buyback. Guidance is maintained, with second half growth expected from IG, albumin, and new products, while competitive and regulatory headwinds persist.
CSL Limited Quarterly report: H1 2026
CSL Limited has published its H1 2026 quarterly earnings report on February 10, 2026.
CSL Limited Slides: H1 2026
CSL Limited has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 10, 2026.
CSL Limited Earnings release: H1 2026
CSL Limited released its H1 2026 earnings on February 10, 2026, summarizing the period's financial results.